137 related articles for article (PubMed ID: 36639903)
1. Colchicine and risk of hospitalization due to COVID-19: A population-based study.
Sáenz-Aldea M; Salgado-Barreira Á; Taracido Trunk M; Piñeiro-Lamas M; Herdeiro MT; Portela-Romero M; Saez M; Figueiras A
J Med Virol; 2023 Feb; 95(2):e28496. PubMed ID: 36639903
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
3. Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.
Diaz R; Orlandini A; Castellana N; Caccavo A; Corral P; Corral G; Chacón C; Lamelas P; Botto F; Díaz ML; Domínguez JM; Pascual A; Rovito C; Galatte A; Scarafia F; Sued O; Gutierrez O; Jolly SS; Miró JM; Eikelboom J; Loeb M; Maggioni AP; Bhatt DL; Yusuf S;
JAMA Netw Open; 2021 Dec; 4(12):e2141328. PubMed ID: 34964849
[TBL] [Abstract][Full Text] [Related]
4. Oxygen Saturation in Hospitalized COVID-19 Patients and Its Relation to Colchicine Treatment: A Retrospective Cohort Study with an Updated Systematic Review.
Sharaf S; Ashmawy R; Saleh E; Salama M; El-Maradny YA; Zari A; Aly S; Tolba A; Mahrous D; Elsayed H; Latif D; Redwan EM; Kamal E
Medicina (Kaunas); 2023 May; 59(5):. PubMed ID: 37241167
[No Abstract] [Full Text] [Related]
5. Effect of dapagliflozin on COVID-19 infection and risk of hospitalization.
Salgado-Barreira A; Seijas-Amigo J; Rodriguez-Mañero M; Piñeiro-Lamas M; Eiras S; Cordero A; Gonzalez-Juanatey JR; Figueiras A
J Antimicrob Chemother; 2023 Sep; 78(9):2335-2342. PubMed ID: 37549309
[TBL] [Abstract][Full Text] [Related]
6. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial.
Deftereos SG; Giannopoulos G; Vrachatis DA; Siasos GD; Giotaki SG; Gargalianos P; Metallidis S; Sianos G; Baltagiannis S; Panagopoulos P; Dolianitis K; Randou E; Syrigos K; Kotanidou A; Koulouris NG; Milionis H; Sipsas N; Gogos C; Tsoukalas G; Olympios CD; Tsagalou E; Migdalis I; Gerakari S; Angelidis C; Alexopoulos D; Davlouros P; Hahalis G; Kanonidis I; Katritsis D; Kolettis T; Manolis AS; Michalis L; Naka KK; Pyrgakis VN; Toutouzas KP; Triposkiadis F; Tsioufis K; Vavouranakis E; Martinèz-Dolz L; Reimers B; Stefanini GG; Cleman M; Goudevenos J; Tsiodras S; Tousoulis D; Iliodromitis E; Mehran R; Dangas G; Stefanadis C;
JAMA Netw Open; 2020 Jun; 3(6):e2013136. PubMed ID: 32579195
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Colchicine anti-inflammatory therapy for non-intensive care unit hospitalized COVID-19 patients: results from a pilot open-label, randomized controlled clinical trial.
Haroon MZ; Farooq U; Ashraf S; Zeb S; Gillani SY; Malik S; Ali R; Irshad R; Mehmood Z; Abbas Y; Masood A; Ghafoor A; Khalil AT; Asif H; Khan S; Ujjan ID; Nigar R; Livingstone S; Pascual-Figal DA; Togni S; Allergini P; Riva A; Khan A
J Physiol Pharmacol; 2022 Jun; 73(3):. PubMed ID: 36302537
[TBL] [Abstract][Full Text] [Related]
9. Reducing length of hospital stay with colchicine.
Karakaş Ö; Erden A; Güven SC; Armağan B; Sahiner ES; Kurtipek AC; Inan O; Gemcioglu E; Ateş İ; Omma A; Küçüksahin O
J Infect Dev Ctries; 2022 Jan; 16(1):57-62. PubMed ID: 35192522
[TBL] [Abstract][Full Text] [Related]
10. Adding Colchicine to the Antiretroviral Medication - Lopinavir/Ritonavir (Kaletra) in Hospitalized Patients with Non-Severe Covid-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomized Controlled Trial.
Dalili N; Kashefizadeh A; Nafar M; Poorrezagholi F; Firouzan A; Samadian F; Samavat S; Ziaie S; Fatemizadeh S
Trials; 2020 Jun; 21(1):489. PubMed ID: 32503620
[TBL] [Abstract][Full Text] [Related]
11. Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational study.
Manenti L; Maggiore U; Fiaccadori E; Meschi T; Antoni AD; Nouvenne A; Ticinesi A; Cerundolo N; Prati B; Delsante M; Gandoflini I; Donghi L; Gentile M; Farina MT; Oliva V; Zambrano C; Regolisti G; Palmisano A; Caminiti C; Cocchi E; Ferrari C; Riella LV; Cravedi P; Peruzzi L
PLoS One; 2021; 16(3):e0248276. PubMed ID: 33760858
[TBL] [Abstract][Full Text] [Related]
12. Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study.
Mareev VY; Orlova YA; Plisyk AG; Pavlikova EP; Akopyan ZA; Matskeplishvili ST; Malakhov PS; Krasnova TN; Seredenina EM; Potapenko AV; Agapov MA; Asratyan DA; Dyachuk LI; Samokhodskaya LM; Mershina ЕА; Sinitsyn VE; Pakhomov PV; Zhdanova EA; Mareev YV; Begrambekova YL; Kamalov АА
Kardiologiia; 2021 Mar; 61(2):15-27. PubMed ID: 33734043
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
14. The impact of COVID-19 on familial Mediterranean fever: a nationwide study.
Günendi Z; Yurdakul FG; Bodur H; Cengiz AK; Uçar Ü; Çay HF; Şen N; Keskin Y; Gürer G; Melikoğlu MA; Altıntaş D; Deveci H; Baykul M; Nas K; Çevik R; Karahan AY; Toprak M; Ketenci S; Nayimoğlu M; Sezer İ; Demir AN; Ecesoy H; Duruöz MT; Yurdakul OV; Sarıfakıoğlu AB; Ataman Ş
Rheumatol Int; 2021 Aug; 41(8):1447-1455. PubMed ID: 34032894
[TBL] [Abstract][Full Text] [Related]
15. Frequency and severity of COVID-19 in patients with various rheumatic diseases treated regularly with colchicine or hydroxychloroquine.
Oztas M; Bektas M; Karacan I; Aliyeva N; Dag A; Aghamuradov S; Cevirgen SB; Sari S; Bolayirli M; Can G; Hatemi G; Seyahi E; Ozdogan H; Gul A; Ugurlu S
J Med Virol; 2022 Jul; 94(7):3431-3437. PubMed ID: 35315100
[TBL] [Abstract][Full Text] [Related]
16. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome of patients with COVID-19 Pneumonia treated with corticosteroids and colchicine in Colombia.
Pinzón MA; Cardona Arango D; Betancur JF; Ortiz S; Holguín H; Arias Arias C; Muñoz Palacio BJ; Amarillo M; Llano JF; Montoya P
Ann Clin Microbiol Antimicrob; 2021 Sep; 20(1):66. PubMed ID: 34521428
[TBL] [Abstract][Full Text] [Related]
18. The effects of colchicine on hospitalized COVID-19 patients: A randomized, double-blind, placebo-controlled clinical trial.
Kasiri H; Ghazaiean M; Rouhani N; Naderi-Behdani F; Ghazaeian M; Ghodssi-Ghassemabadi R
J Investig Med; 2023 Feb; 71(2):124-131. PubMed ID: 36647298
[TBL] [Abstract][Full Text] [Related]
19. Effect of Previous Anticoagulant Treatment on Risk of COVID-19.
Zapata-Cachafeiro M; Prieto-Campo Á; Portela-Romero M; Carracedo-Martínez E; Lema-Oreiro M; Piñeiro-Lamas M; Chaudhuri S; Salgado-Barreira Á; Figueiras A
Drug Saf; 2023 Mar; 46(3):273-281. PubMed ID: 36562942
[TBL] [Abstract][Full Text] [Related]
20. Predictive risk factors for hospitalization and response to colchicine in patients with COVID-19.
Tardif JC; Cossette M; Guertin MC; Bouabdallaoui N; Dubé MP; Boivin G;
Int J Infect Dis; 2022 Mar; 116():387-390. PubMed ID: 35038601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
